NA-931

Biomed Industries, Inc. · Phase 2 active Small molecule

NA-931 is a Small molecule drug developed by Biomed Industries, Inc.. It is currently in Phase 2 development. Also known as: NA-931 is a quadruple receptor agonist, Tirzepatide placebo, Tirzepatide.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

• Baseline phase 2 → approval rate +15.3pp
  Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NA-931
Also known as	NA-931 is a quadruple receptor agonist, Tirzepatide placebo, Tirzepatide
Sponsor	Biomed Industries, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (PHASE2)
• Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition (PHASE2)
• Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NA-931 CI brief — competitive landscape report
• NA-931 updates RSS · CI watch RSS
• Biomed Industries, Inc. portfolio CI

Frequently asked questions about NA-931

What is NA-931?

NA-931 is a Small molecule drug developed by Biomed Industries, Inc..

Who makes NA-931?

NA-931 is developed by Biomed Industries, Inc. (see full Biomed Industries, Inc. pipeline at /company/biomed-industries-inc).

Is NA-931 also known as anything else?

NA-931 is also known as NA-931 is a quadruple receptor agonist, Tirzepatide placebo, Tirzepatide.

What development phase is NA-931 in?

NA-931 is in Phase 2.

Related

• Manufacturer: Biomed Industries, Inc. — full pipeline
• Also known as: NA-931 is a quadruple receptor agonist, Tirzepatide placebo, Tirzepatide